Vincent C. Njar - Publications

Affiliations: 
Molecular Medicine University of Maryland School of Medicine, Baltimore, MD, United States 
Area:
Pharmacology, Molecular Biology, Physiology Biology

52 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kwegyir-Afful AK, Ramalingam S, Ramamurthy VP, Purushottamachar P, Murigi FN, Vasaitis TS, Huang W, Kane MA, Zhang Y, Ambulos N, Tiwari S, Srivastava P, Nnane IP, Hussain A, Qiu Y, ... ... Njar VCO, et al. Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo. Cancers. 11. PMID 31653008 DOI: 10.3390/cancers11111637  0.8
2019 Ramalingam S, Ramamurthy VP, Gediya LK, Murigi FN, Purushottamachar P, Huang W, Choi EY, Zhang Y, Vasaitis TS, Kane MA, Lapidus RG, Njar VCO. The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis. Cancers. 11. PMID 30832411 DOI: 10.3390/cancers11030299  0.8
2018 Ramamurthy VP, Ramalingam S, Gediya LK, Njar VCO. The retinamide VNLG-152 inhibits AR/AR-V7 and MNK-eIF4Esignaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth. The Febs Journal. PMID 29323792 DOI: 10.1111/febs.14383  0.8
2017 Njar VCO. Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy. Translational Cancer Research. 6: S1128-S1131. PMID 30613487 DOI: 10.21037/tcr.2017.08.29  0.6
2017 McCarty DJ, Huang W, Kane MA, Purushottamachar P, Gediya LK, Njar VCO. Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model. Oncotarget. 8: 88501-88516. PMID 29179452 DOI: 10.18632/oncotarget.19762  0.8
2017 Kwegyir-Afful AK, Murigi FN, Purushottamachar P, Ramamurthy VP, Martin MS, Njar VCO. Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. Oncotarget. 8: 52381-52402. PMID 28881737 DOI: 10.18632/oncotarget.14154  0.8
2017 Ramamurthy VP, Ramalingam S, Kwegyir-Afful AK, Hussain A, Njar VC. Targeting of protein translation as a new treatment paradigm for prostate cancer. Current Opinion in Oncology. PMID 28282343 DOI: 10.1097/CCO.0000000000000367  0.56
2016 Kwegyir-Afful AK, Murigi FN, Purushottamachar P, Ramamurthy VP, Martin MS, Njar VC. Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. Oncotarget. PMID 28030797 DOI: 10.18632/oncotarget.14154  0.8
2016 Kwegyir-Afful AK, Bruno RD, Purushottamachar P, Murigi FN, Njar VC. Galeterone and VNPT55 disrupts Mnk-eIF4E to inhibit prostate cancer cell migration and invasion. The Febs Journal. PMID 27618366 DOI: 10.1111/febs.13895  1
2016 Senthilmurugan R, Ramamurthy VP, Njar VC. Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. The Journal of Steroid Biochemistry and Molecular Biology. PMID 27481707 DOI: 10.1016/j.jsbmb.2016.07.006  0.32
2016 Purushottamachar P, Kwegyir-Afful AK, Martin MS, Ramamurthy VP, Ramalingam S, Njar VC. Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate. Acs Medicinal Chemistry Letters. 7: 708-13. PMID 27437082 DOI: 10.1021/acsmedchemlett.6b00137  0.8
2015 Kwegyir-Afful AK, Ramalingam S, Purushottamachar P, Ramamurthy VP, Njar VC. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget. 6: 27440-60. PMID 26196320 DOI: 10.18632/oncotarget.4578  0.8
2015 Mbatia HW, Ramalingam S, Ramamurthy VP, Martin MS, Kwegyir-Afful AK, Njar VC. Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice. Journal of Medicinal Chemistry. 58: 1900-14. PMID 25634130 DOI: 10.1021/jm501792c  0.8
2015 Ramamurthy VP, Ramalingam S, Gediya L, Kwegyir-Afful AK, Njar VC. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines. Oncotarget. 6: 3195-210. PMID 25605250 DOI: 10.18632/oncotarget.3084  0.56
2015 Njar VC, Brodie AM. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. Journal of Medicinal Chemistry. 58: 2077-87. PMID 25591066 DOI: 10.1021/jm501239f  0.32
2014 Godbole AM, Ramalingam S, Ramamurthy VP, Khandelwal A, Bruno RD, Upreti VV, Gediya LK, Purushottamachar P, Mbatia HW, Addya S, Ambulos N, Njar VC. VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. European Journal of Pharmacology. 734: 98-104. PMID 24726842 DOI: 10.1016/j.ejphar.2014.04.004  0.8
2014 Ramalingam S, Gediya L, Kwegyir-Afful AK, Ramamurthy VP, Purushottamachar P, Mbatia H, Njar VC. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget. 5: 530-43. PMID 24504069 DOI: 10.18632/oncotarget.1528  0.8
2013 Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis TS, Kwegyir-Afful AK, Ramalingam S, Ates-Alagoz Z, Njar VC. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. Journal of Medicinal Chemistry. 56: 4880-98. PMID 23713567 DOI: 10.1021/jm400048v  0.8
2013 Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis. 34: 199-210. PMID 23042302 DOI: 10.1093/carcin/bgs319  0.8
2012 Purushottamachar P, Njar VC. A new simple and high-yield synthesis of 5α-dihydrotestosterone (DHT), a potent androgen receptor agonist. Steroids. 77: 1530-4. PMID 23044354 DOI: 10.1016/j.steroids.2012.09.003  0.8
2012 Godbole AM, Purushottamachar P, Martin MS, Njar VC. Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. Cancer Chemotherapy and Pharmacology. 70: 339-44. PMID 22580781 DOI: 10.1007/s00280-012-1877-z  0.8
2012 Godbole AM, Purushottamachar P, Martin MS, Daskalakis C, Njar VC. Autophagy inhibition synergistically enhances anticancer efficacy of RAMBA, VN/12-1 in SKBR-3 cells, and tumor xenografts. Molecular Cancer Therapeutics. 11: 898-908. PMID 22334589 DOI: 10.1158/1535-7163.MCT-11-0860  0.8
2012 Purushottamachar P, Patel JB, Gediya LK, Clement OO, Njar VC. First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. European Journal of Medicinal Chemistry. 47: 412-23. PMID 22130607 DOI: 10.1016/j.ejmech.2011.11.010  0.8
2012 Goss PE, Qi S, Hu H, Gediya LK, Purushottamachar P, Godbole AM, Njar VC. Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus. Breast Cancer Research and Treatment. 133: 137-44. PMID 21842418 DOI: 10.1007/s10549-011-1724-7  0.8
2011 Godbole AM, Njar VC. New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer. 2011: 918707. PMID 22111003 DOI: 10.1155/2011/918707  1
2011 Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids. 76: 1268-79. PMID 21729712 DOI: 10.1016/j.steroids.2011.06.002  0.8
2011 Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. The Journal of Steroid Biochemistry and Molecular Biology. 125: 23-31. PMID 21092758 DOI: 10.1016/j.jsbmb.2010.11.005  0.8
2010 Vasaitis TS, Njar VC. Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments. Future Medicinal Chemistry. 2: 667-80. PMID 21426013 DOI: 10.4155/fmc.10.14  0.8
2010 Swanson HI, Njar VC, Yu Z, Castro DJ, Gonzalez FJ, Williams DE, Huang Y, Kong AN, Doloff JC, Ma J, Waxman DJ, Scott EE. Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 539-44. PMID 20233842 DOI: 10.1124/dmd.109.031351  0.8
2009 Dexheimer TS, Gediya LK, Stephen AG, Weidlich I, Antony S, Marchand C, Interthal H, Nicklaus M, Fisher RJ, Njar VC, Pommier Y. 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. Journal of Medicinal Chemistry. 52: 7122-31. PMID 19883083 DOI: 10.1021/jm901061s  0.8
2008 Bruno RD, Gover TD, Burger AM, Brodie AM, Njar VC. 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Molecular Cancer Therapeutics. 7: 2828-36. PMID 18790763 DOI: 10.1158/1535-7163.MCT-08-0336  1
2008 Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics. 7: 2348-57. PMID 18723482 DOI: 10.1158/1535-7163.MCT-08-0230  0.8
2008 Moreira VM, Vasaitis TS, Guo Z, Njar VC, Salvador JA. Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth. Steroids. 73: 1217-27. PMID 18582482 DOI: 10.1016/j.steroids.2008.05.010  0.8
2008 Gediya LK, Khandelwal A, Patel J, Belosay A, Sabnis G, Mehta J, Purushottamachar P, Njar VC. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. Journal of Medicinal Chemistry. 51: 3895-904. PMID 18543902 DOI: 10.1021/jm8001839  0.8
2008 Purushottamachar P, Khandelwal A, Vasaitis TS, Bruno RD, Gediya LK, Njar VC. Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorganic & Medicinal Chemistry. 16: 3519-29. PMID 18316193 DOI: 10.1016/j.bmc.2008.02.031  0.8
2008 Schayowitz A, Sabnis G, Njar VC, Brodie AM. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Molecular Cancer Therapeutics. 7: 121-32. PMID 18202015 DOI: 10.1158/1535-7163.MCT-07-0581  0.56
2008 Gediya LK, Belosay A, Khandelwal A, Purushottamachar P, Njar VC. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorganic & Medicinal Chemistry. 16: 3352-60. PMID 18166465 DOI: 10.1016/j.bmc.2007.12.007  0.8
2007 Moreira VM, Vasaitis TS, Njar VC, Salvador JA. Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors. Steroids. 72: 939-48. PMID 17884122 DOI: 10.1016/j.steroids.2007.08.004  0.8
2007 Bruno RD, Njar VC. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorganic & Medicinal Chemistry. 15: 5047-60. PMID 17544277 DOI: 10.1016/j.bmc.2007.05.046  1
2007 Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR, Njar VC. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. British Journal of Cancer. 96: 1204-15. PMID 17387344 DOI: 10.1038/sj.bjc.6603705  0.8
2007 Purushottamachar P, Khandelwal A, Chopra P, Maheshwari N, Gediya LK, Vasaitis TS, Bruno RD, Clement OO, Njar VC. First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorganic & Medicinal Chemistry. 15: 3413-21. PMID 17383188 DOI: 10.1016/j.bmc.2007.03.019  0.8
2007 Patel JB, Khandelwal A, Chopra P, Handratta VD, Njar VC. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. Cancer Chemotherapy and Pharmacology. 60: 899-905. PMID 17345084 DOI: 10.1007/s00280-007-0438-3  0.8
2006 Belosay A, Brodie AM, Njar VC. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Cancer Research. 66: 11485-93. PMID 17145897 DOI: 10.1158/0008-5472.CAN-06-2168  0.8
2006 Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 10: 309-19. PMID 17045208 DOI: 10.1016/j.ccr.2006.08.021  0.48
2006 Njar VC, Gediya L, Purushottamachar P, Chopra P, Belosay A, Patel JB. Retinoids in clinical use. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 2: 431-8. PMID 16848757  0.8
2006 Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorganic & Medicinal Chemistry. 14: 4323-40. PMID 16530416 DOI: 10.1016/j.bmc.2006.02.041  0.8
2005 Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Njar VC. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. Journal of Medicinal Chemistry. 48: 5047-51. PMID 16033284 DOI: 10.1021/jm058214k  0.8
2005 Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, Brodie AM. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of Medicinal Chemistry. 48: 2972-84. PMID 15828836 DOI: 10.1021/jm040202w  0.8
2004 Patel JB, Huynh CK, Handratta VD, Gediya LK, Brodie AM, Goloubeva OG, Clement OO, Nanne IP, Soprano DR, Njar VC. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. Journal of Medicinal Chemistry. 47: 6716-29. PMID 15615521 DOI: 10.1021/jm0401457  0.8
2004 Handratta VD, Jelovac D, Long BJ, Kataria R, Nnane IP, Njar VC, Brodie AM. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. The Journal of Steroid Biochemistry and Molecular Biology. 92: 155-65. PMID 15555909 DOI: 10.1016/j.jsbmb.2004.07.006  0.48
2003 Clement OO, Freeman CM, Hartmann RW, Handratta VD, Vasaitis TS, Brodie AM, Njar VC. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. Journal of Medicinal Chemistry. 46: 2345-51. PMID 12773039 DOI: 10.1021/jm020576u  0.8
2003 Nnane IP, Njar VC, Brodie AM. Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice. Cancer Chemotherapy and Pharmacology. 51: 519-24. PMID 12715204 DOI: 10.1007/s00280-003-0603-2  0.32
Show low-probability matches.